1. Home
  2. NOV vs GKOS Comparison

NOV vs GKOS Comparison

Compare NOV & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOV Inc.

NOV

NOV Inc.

HOLD

Current Price

$18.42

Market Cap

6.9B

Sector

Industrials

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$119.46

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOV
GKOS
Founded
1862
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.3B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
NOV
GKOS
Price
$18.42
$119.46
Analyst Decision
Hold
Strong Buy
Analyst Count
13
14
Target Price
$16.62
$132.00
AVG Volume (30 Days)
4.5M
867.6K
Earning Date
02-04-2026
02-17-2026
Dividend Yield
1.61%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
$8,775,000,000.00
$469,820,000.00
Revenue This Year
N/A
$32.39
Revenue Next Year
N/A
$23.05
P/E Ratio
$18.67
N/A
Revenue Growth
N/A
30.38
52 Week Low
$10.84
$73.16
52 Week High
$19.22
$161.78

Technical Indicators

Market Signals
Indicator
NOV
GKOS
Relative Strength Index (RSI) 60.36 54.01
Support Level $18.18 $116.73
Resistance Level $19.20 $128.84
Average True Range (ATR) 0.52 6.39
MACD -0.00 -0.18
Stochastic Oscillator 57.08 70.03

Price Performance

Historical Comparison
NOV
GKOS

About NOV NOV Inc.

NOV (formerly National Oilwell Varco) is a leading supplier of oil and gas drilling rig equipment and products, such as downhole tools, drill pipe, and well casing. The company operates on a global scale, with international markets contributing nearly two thirds of its annual revenue.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: